These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25343963)

  • 1. Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D).
    Saw RP; Armstrong BK; Mason RS; Morton RL; Shannon KF; Spillane AJ; Stretch JR; Thompson JF
    BMC Cancer; 2014 Oct; 14():780. PubMed ID: 25343963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    De Smedt J; Van Kelst S; Boecxstaens V; Stas M; Bogaerts K; Vanderschueren D; Aura C; Vandenberghe K; Lambrechts D; Wolter P; Bechter O; Nikkels A; Strobbe T; Emri G; Marasigan V; Garmyn M
    BMC Cancer; 2017 Aug; 17(1):562. PubMed ID: 28835228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
    Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
    Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.
    Coventry BJ; Kroon HM; Giles MH; Henderson M; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM
    J Surg Oncol; 2014 Jun; 109(8):780-5. PubMed ID: 24634160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
    Lipplaa A; Fernandes R; Marshall A; Lorigan P; Dunn J; Myers KA; Barker E; Newton-Bishop J; Middleton MR; Corrie PG
    Br J Cancer; 2018 Oct; 119(7):793-800. PubMed ID: 30033445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Malignant melanoma].
    Matsumoto K; Saida T
    Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
    Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
    Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
    Cafiero F; Gipponi M; Lionetto R;
    J Surg Oncol; 2003 Jul; 83(3):140-6. PubMed ID: 12827681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial.
    Nair-Shalliker V; Smith DP; Gebski V; Patel MI; Frydenberg M; Yaxley JW; Gardiner R; Espinoza D; Kimlin MG; Fenech M; Gillatt D; Woo H; Armstrong BK; Rasiah K; Awad N; Symons J; Gurney H
    BMJ Open; 2021 Mar; 11(3):e044055. PubMed ID: 33653757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary mucosal melanoma of the head and neck. Comparison of clinical presentation and histopathologic features of oral and sinonasal melanoma.
    McLean N; Tighiouart M; Muller S
    Oral Oncol; 2008 Nov; 44(11):1039-46. PubMed ID: 18396446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
    Slingluff CL; Lewis KD; Andtbacka R; Hyngstrom J; Milhem M; Markovic SN; Bowles T; Hamid O; Hernandez-Aya L; Claveau J; Jang S; Philips P; Holtan SG; Shaheen MF; Curti B; Schmidt W; Butler MO; Paramo J; Lutzky J; Padmanabhan A; Thomas S; Milton D; Pecora A; Sato T; Hsueh E; Badarinath S; Keech J; Kalmadi S; Kumar P; Weber R; Levine E; Berger A; Bar A; Beck JT; Travers JB; Mihalcioiu C; Gastman B; Beitsch P; Rapisuwon S; Glaspy J; McCarron EC; Gupta V; Behl D; Blumenstein B; Peterkin JJ
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality.
    Fogarty GB; Hong A; Dolven-Jacobsen K; Reisse CH; Burmeister B; Haydu LH; Dhillon H; Steel V; Shivalingam B; Drummond K; Vardy J; Nowak A; Hruby G; Scolyer RA; Mandel C; Thompson JF
    BMC Res Notes; 2015 May; 8():192. PubMed ID: 25952979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial).
    De Smedt J; Van Kelst S; Janssen L; Marasigan V; Boecxstaens V; Bogaerts K; Belmans A; Vanderschueren D; Vandenberghe K; Bechter O; Aura C; Lambrechts D; Strobbe T; Emri G; Nikkels A; Garmyn M
    Br J Dermatol; 2024 Nov; 191(6):886-896. PubMed ID: 38913652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.